We are grateful to all our sponsors and partners for their generous support of the Congress.
The organising committee of the 18th World Congress of the International Society on Toxinology are grateful to BTG Plc for their generous educational grant to support the organisation of the Congress.
BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. BTG has a portfolio of Interventional Medicine products to advance the treatment of liver tumours, severe blood clots, varicose veins and advanced emphysema, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins.
To learn more about BTG, please visit: www.btgplc.com.
Silver Sponsor and Exhibitor
Silanes was born on November 4, 1943 as a medical prescription laboratory. Today is a solid company that has evolved according to the requirements of quality and innovation maintaining a tradition of trust and commitment to its various stakeholders, such as doctors and members of the health sector, employees, customers, partners, researchers, suppliers, authorities, etc., with the motivation of the world every day to provide better solutions to health.
We are an innovative company that set aside 10% of our sales to research and development, patents and generators being agreements academia-industry collaboration. Aware of the challenges imposed on us by an increasingly globalized world, we seek to expand our coverage to other countries by forming strategic alliances with companies in the industry with the launch of a subsidiary in Spain that allows us to generate innovative projects in other continents.
The Instituto Bioclon is a subusidiary company of Silanes and came about as a result of this union 1990. It emerged to take advantage of the opportunities for developing new biotechnologies and for becoming a world leader in the research, development, and production.
Bioclon-Silanes is the creator of third generation antivenoms of worldwide level, whose biotechnological characteristics make them different, that are highly safe, broadly efficacious, and having had no reports of severe secondary effects. They are produced using a technology that is 100% that of Bioclon-Silanes, and protected by patents in several countries. Our antivenoms are currently marketed in Mexico, Central and South America, United States of America, Europe, Africa, and the Middle East through a regionalization program
Bioclon-Silanes is the only Mexican company that has obtained the designation “orphan drug” (the non-existence of a drug or medication for treating a specific disease) by the Food and Drug Administration (FDA) of the United States of America.
Silver Sponsor and Exhibitor
..more information to follow soon..
Delegate Bag Sponsor
Ipsen is a global specialty-driven pharmaceutical company with total sales in 2013 exceeding €1.2 billion. Ipsen also has a significant presence in primary care. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by three franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen’s internal R&D is focused on two technology platforms: peptides and toxins. Its aim is to develop its expertise in these two platforms with the objective of increasing its understanding of both basic sciences and clinical aspects. In 2013, R&D expenditure totalled close to €196 million, representing more than 16% of Group sales.
MicroPharm Limited is a developer and manufacturer of therapeutic polyclonal antibodies for human and veterinary use. The Company’s core expertise lies in the raising of ovine antisera containing high levels of specific antibodies directed against antigens such as toxic molecules or viruses and the subsequent purification and modification of such antibodies to produce a range of immunotherapeutic products for clinical use. All are designed to treat acute, life-threatening emergencies, have been developed at the request of the medical profession and are required urgently either because no alternative exists or because any alternative is ineffective and/or unsafe. MicroPharm currently produces two antivenoms, ViperaTAb® for the treatment of envenomation by the European adder and EchiTAbG™ for the treatment of the carpet viper, Echis ocellatus. The Company has a number of products in development including: PolyCAb for the treatment of severe C. diff.; ColchiBIND for the treatment of colchicine poisoning; EBOTAb for the treatment of Ebola Virus Disease and ViperaVet™, for the treatment of dogs envenomed by one of the four medically important species of Vipera (adder) found throughout Western Europe. MicroPharm’s collaborators include Public Health England, University of Oxford, University of Leeds and the University of Edinburgh.
VINS Bioproducts Limited entered the arena of biologicals and bio-pharmaceuticals at the turn of the century with a view to produce life saving drugs for rural areas. Early on, the company focused on finding remedies for diseases that are endemic in India, the tropics and other less developed nations. True to its initial objective, the company commenced work to develop AntiSnake Venom Serum (ASVS), which was launched in early 2000. VINS’ ASVS, is a life saving product much needed in rural areas where people engaged in agriculture activities are regularly exposed to snake bites.
The product was well accepted and enjoys today, a market share of almost 40% of the Indian ASVS market. Spurred on by the initial success, the company took up the development of ASVS (Polyvalent from different African snake species including for deadly Black Mamba species). Today Vins manufactures several Snake Venom Antiserum country specific to the requirement by the MOH of various countries.
Anti Rabies Serum (ARS). World Health Organization (W.H.O.) estimates that 75% of deaths caused by rabies world-wide, occur in India, Bangladesh and Pakistan alone. W.H.O. recommends Anti Rabies Serum (ARS) along with anti rabies vaccine (ARV) to be injected in all Category III and immuno- compromised Category II rabies cases. The other products are Tetanus Antitoxin, and Diphtheria Antitoxin.
Toxins (ISSN 2072-6651, Impact factor 2.480 in 2013) is an open access, peer-reviewed journal led by Dr. Vernon Tesh from Texas A&M University System Health Science Center. The journal publishes articles on toxinology and all kinds of biotoxins, including toxins from animals, microbes and plants. Topics include: aflatoxins, snake venoms, enterotoxins and ricins. We welcome submissions of original research articles, reviews, communications and conference letters.
By publishing in Toxins, you can take advantage of:
- Open Access: unlimitted and free access by readers, authors retain copyright;
- High publicity and more frequent citations;
- Thorough and rigorous peer-review;
- Fast manuscript handling time: a first decision provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 10 days;
- Coverage by leading indexing services: SCIE Web of Science, Scopus, PubMed, etc;
- No space constraints: no restriction on the length of the papers, electronic files can be deposited as supplementary material
Journal of Venom Research (ISSN: 2044-0324) is an open-access, peer-reviewed journal, publishing high-quality articles addressing most aspects of therapeutic, molecular, biochemical and evolutionary research on venoms, and envenomation. The Journal is edited by Dr Edward Rowan (University of Strathclyde, UK) and a highly-distinguished group of venom researchers as members of its Editorial Board.
The Journal has high visibility and is listed in several major indexing databases including, PubMed Central/PubMed • UKPMC • PMC Canada, •The Directory of Open Access Journals • Google Scholar • OPEN J-Gate • Chemical Abstracts Service (CAS) • Academic Search Complete (EBSCO).
The Journal is pleased to waive basic open-access article processing fee of IST 2015 Oxford delegates and invites short and full research articles, reviews and mini-reviews, clinical reports,case studies, and new methods and technologies. Please visit the Journal website and links therein for further information about manuscript preparation and submission process.
The Kentucky Reptile Zoo has provided quality venom to customers around the world for over 20 years. We are dedicated not only to providing quality venom, but to the conservation of reptiles as well the environment they inhabit. Our venom is collected from healthy individuals and our non-invasive techniques insure all individuals are unharmed. Many of our snakes live longer than their average life span. Snakes used for extraction have passed quarantine, feed voluntarily and produce viable offspring if breeding is intended. All venoms are collected in a sterile manner and frozen at -70oC before lyophilization. CITES permits are available for all CITIES listed species. Locale information is available for many species. Feel free to contact us with any questions.
Alphabiotoxine has a twenty year expertise in venomous animals handling and is a trustworthy partner for venom production since 2009. We work hard to find healthy animals, maintain them in the best conditions and develop techniques of venom extraction to meet the highest quality standards. We currently propose the highest diversity of venoms in the world. We can help with all aspects of your research working by your side to define the best strategy for your project. Our values are: Quality, Ethics and Service. Contact us before 31st of December 2015 and get a 15% discount to boost your research!
The Global Snakebite Initiative (http://www.snakebiteinitiative.org) is an internationally-active, non-profit, charitable organisation, registered in Australia, but with world-wide vision, aims and membership. It is led by snake-bite experts who are dedicated to improving access to good quality, robustly tested, safe, effective antivenoms in the world’s poorest communities. It strives to provide a collaborative framework to address the neglected global tragedy of snake-bite envenoming. The Global Snakebite Initiative has been endorsed by the membership of the International Society on Toxinology (IST), and many of the GSI members are also members of the IST. GSI’s delegation at the Oxford Congress will be led by its Chief Executive Officer (Dr David J Williams), the chair of its Scientific Advisory Committee (Dr José María Gutiérrez) and the senior member of its Board of Directors (Professor David A Warrell).
The French Society on Toxinology (SFET: http://sfet.asso.fr/international/) was created in 1993 by highly motivated French toxinologists (Drs S. Puiseux-Dao, M. Goyffon, C. Bon, A. Ménez, F. Goudey-Pérrière…) with the goal:
- To promote in France the development of research in all areas concerning animal, plant and microbial toxins: modes of action, use in the analysis of the structure and functioning of their molecular targets, biotechnology and chemistry.
- To favour exchanges between researchers by the organization of an annual meeting of two days, held in December in Paris. These “Meetings in Toxinology” were focused each year on one specific topic that gathers animal and microbial toxinologists community (assistance greater than 100 persons). The last meetings were focused on:
- “Toxins: New Targets and New Functions” (RT22)
- “Freshwater and Marine Toxins” (RT21)
- “Toxins: From Threats to Benefits” (RT20)
- “Toxins and Ion Transfers” (RT19)
Articles and review presented during this meeting were initially published by Lavoisier library (2001-2007), then in an ebook (2008-2011) and since four years in a special issue of Toxicon.
- To stimulate the relations between fundamental and applied research.
- To contribute to the continuous progress of scientific and technical level in toxinology and participate to the education of students in this field.
SFET will give two prizes of 500 Euros each for the two posters judged by an expert panel of co-chairs/organisers as being the best at the Congress. The SFET representatives in charge of the poster awards will be: E. Benoit, M-F. Martine-Eauclaire, G. Faure, J. Molgo, N. Gilles and D. Servent. The prize ceremony will take place on 30th September.
Nasreen & Zoeb Sachee (Support for delegates from earthquake-torn Nepal)